At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 69 enrolled
Drug / intervention
Minocin (minocycline) for Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics of Minocin® (Minocycline) for Injection in Healthy Adult Subjects
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)·interventional·Posted Jun 16, 2016·Updated Dec 15, 2023
In Brief
A Phase 1 clinical trial evaluating Minocin (minocycline) for Injection and Placebo for Normal Healthy Volunteers. Completed, enrolled 69 participants across 1 site.
Detailed Summary
This was a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study of the safety, tolerability, and pharmacokinetics of Minocin (minocycline) for injection in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Healthy Volunteers
CountriesNetherlands
CollaboratorsUniversitätsklinikum Köln, Innovative Medicines Initiative
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartApr 2017
Primary CompletionFeb 2018
TodayJul 2026
First PostedJun 16, 2016
Enrollment StartApr 20, 2017
Primary CompletionFeb 8, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.0 years ago
Interventions
Minocin (minocycline) for Injectiondrug
Intravenous formulation of minocycline, a derivative of tetracycline
Placeboother
Placebo - Normal Saline